Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2021-03-25

FDA Approved: MYRBETRIQ — Supplemental Application (Astellas Pharma US, Inc.)

View source ↗

Summary

FDA has approved a supplemental application for MYRBETRIQ (mirabegron) from Astellas US, resulting in changes to the product labeling. The action may include ex…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Myrbetriq (mirabegron)

Snippet

SUPPL AP for MYRBETRIQ (MIRABEGRON)